Sophocarpine attenuates liver fibrosis by inhibiting the TLR4 signaling pathway in rats

Table 2 Effect of sophocarpine on the improvement in serum alanine aminotransferase, aspartate aminotransferase and total bilirubin levels in both models of liver fibrosis

Group	ALT (U/L)	AST (U/L)	TB (mmol/L)
Normal	29.29 ± 1.76	123.67 ± 29.06	1.29 ± 0.28
DMN model	68.27 ± 3.43	176.9 ± 8.99	8.09 ± 1.35
DMN + sophocarpine	48.58 ± 4.521	108.42 ± 15.461	3.00 ± 0.481
Sham operation	28.83 ± 2.22	121.00 ± 36.72	2.00 ± 0.63
BDL model	150.50 ± 23.6	959.50 ± 255	139.67 ± 16.23
BDL + sophocarpine	91.86 ± 6.711	464.14 ± 182.61	123.86 ± 9.69

¹Compared with the model group, P < 0.05. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TB: Total bilirubin; DMN: Dimethylnitrosamine; BDL: Bile duct ligation.